Matinas BioPharma Nanotechnologies, Inc.
Quick facts
Phase 3 pipeline
- MAT2203 · Infectious Disease
MAT2203 is a lipid nanoparticle formulation of amphotericin B designed to improve drug delivery and reduce toxicity in fungal infections.
Phase 2 pipeline
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors: